Edwards Lifesciences Corporation revenue by year
Over the 10 fiscal years shown, revenue went from $2.96B (year ended Dec 31, 2016) to $6.07B (year ended Dec 31, 2025), a compound annual growth rate of 8.3%. The fastest growth was +19.3% in the year ended Dec 31, 2021; the weakest year was −14.7% (year ended Dec 31, 2022).
Annual revenue
| Fiscal year ended | Revenue (USD) | Change | XBRL concept | Reported in |
|---|---|---|---|---|
| Dec 31, 2025 | $6.07B | +11.5% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 25, 2026 |
| Dec 31, 2024 | $5.44B | +8.6% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 25, 2026 |
| Dec 31, 2023 | $5.01B | +12.2% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 25, 2026 |
| Dec 31, 2022 | $4.46B | −14.7% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 28, 2025 |
| Dec 31, 2021 | $5.23B | +19.3% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 12, 2024 |
| Dec 31, 2020 | $4.39B | +0.9% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 13, 2023 |
| Dec 31, 2019 | $4.35B | +16.8% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 14, 2022 |
| Dec 31, 2018 | $3.72B | +8.4% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 12, 2021 |
| Dec 31, 2017 | $3.44B | +15.9% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 14, 2020 |
| Dec 31, 2016 | $2.96B | +18.8% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 15, 2019 |
Quarterly revenue
Quarters reported in 10-Q filings. Fourth quarters are usually reported only inside the annual 10-K, so they are not listed separately here; we do not estimate them.
| Quarter | Revenue (USD) | vs same quarter a year earlier | Source |
|---|---|---|---|
| 3 months ended Jun 30, 2026 | $1.74B | +13.6% | 10-Q filed Aug 4, 2026 |
| 3 months ended Mar 31, 2026 | $1.65B | +16.7% | 10-Q filed May 6, 2026 |
| 3 months ended Sep 30, 2025 | $1.55B | +14.7% | 10-Q filed Nov 5, 2025 |
| 3 months ended Jun 30, 2025 | $1.53B | +11.9% | 10-Q filed Aug 4, 2026 |
| 3 months ended Mar 31, 2025 | $1.41B | +6.2% | 10-Q filed May 6, 2026 |
| 3 months ended Sep 30, 2024 | $1.35B | +8.9% | 10-Q filed Nov 5, 2025 |
| 3 months ended Jun 30, 2024 | $1.37B | +5.7% | 10-Q filed Aug 6, 2025 |
| 3 months ended Mar 31, 2024 | $1.33B | −8.9% | 10-Q filed May 6, 2025 |
Source: SEC EDGAR XBRL company facts for CIK 1099800 (raw data). Most recent filing in this dataset: 10-Q filed Aug 4, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.